Christopher P. Shryock - 16 Dec 2025 Form 4 Insider Report for Medline Inc. (MDLN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Mar 2026, 16:30:16 UTC
Next SEC filing
17 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nicole Fritz, Attorney-in-Fact

Key filing fact

Christopher P. Shryock filed Form 4 for Medline Inc. (MDLN) on 06 Mar 2026.

Key facts

  • This page summarizes Christopher P. Shryock's Form 4 filing for Medline Inc. (MDLN).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 06 Mar 2026, 16:30.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002061070 Primary reporting owner

Shryock Christopher P

Relationship
Chief Human Resources Officer
Address
C/O MEDLINE INC., 3 LAKES DRIVE, NORTHFIELD
Signature
/s/ Nicole Fritz, Attorney-in-Fact
Signature date
06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDLN transaction

Class A Common Stock

Award

Transaction value
Shares
+11,903
Change %
Price
$0.000000*
Shares after
11,903
Date
05 Mar 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares
+496,049
Change %
Price
Shares after
496,049
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
496,049
Exercise price
$24.19
Footnotes
F2, F3, F4, F5
MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares
+40,638
Change %
Price
Shares after
40,638
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
40,638
Exercise price
$27.68
Footnotes
F2, F3, F4, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents a grant of restricted stock units, of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027.

Footnote F2

Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of common units of Medline Holdings, LP ("Common Units") generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of the Issuer's Class A common stock ("Class A Common Stock")) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.

Footnote F3

(Continued from Footnote 2 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of an exchange agreement, dated as of December 16, 2025. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.

Footnote F4

These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.

Footnote F5

20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on September 27, 2026.

Footnote F6

These Incentive Units vest in five equal annual installments beginning on March 28, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .